当前位置： SCI文献检索 > DRUG SAFETY期刊下所有文献 > Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.

Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.

Abstract：

:Women who discover they are pregnant after exposure to a drug and pregnant women who have a condition that requires continued treatment during pregnancy are told to balance the benefits and risks of the exposure to justify continuation of treatment, discontinuation of treatment or, possibly, pregnancy termination. However, there are limited data available to inform decision-making. The Merck Pregnancy Registry Program is a company-run pregnancy registry whose objective is to acquire and analyse information on drug exposures and pregnancy outcomes to better describe the safety profile of Merck products used during pregnancy. Information is collected from women and healthcare providers who call to report drug exposure during pregnancy. Prospective pregnancies are followed up to outcome and data are collected via questionnaires, telephone calls and a review of medical records. Reports are classified as prospective (information received prior to knowledge of pregnancy outcome) or retrospective (received after the outcome is known). Congenital anomaly reports are assessed for timing of exposure, maternal age and medical history, biological plausibility and concomitant medication exposures. Rates of pregnancy outcomes and birth defects in the prospective cohort are computed and confidence intervals are calculated to reflect the strength of the finding based on the sample size. Rates of pregnancy outcomes in the Pregnancy Registry are compared with the rates of pregnancy outcomes in the general US population and, if available, in subpopulations with the relevant disease states. The limitations of post-marketing surveillance are well known as voluntary reporting of individuals and healthcare professionals is known to be subject to various types of bias. Small sample size is another major limitation. However, the strength of the registry lies in its ability to gather pregnancy outcome reports early in the life of a product and to recognise and analyse unusual birth defects. Our data suggest that pregnancy registries can be used to review human exposure data in a systematic fashion so that useful information can be shared with women and their healthcare providers. The use of the pregnancy registry design has allowed for the collection and analysis of data on the effects of drug exposures on human pregnancies that have otherwise been difficult to obtain.

journal_name

Drug Saf

journal_title

Drug safety

authors

Shields KE,Wiholm BE,Hostelley LS,Striano LF,Arena SR,Sharrar RG

doi

10.2165/00002018-200427060-00001

keywords:

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

353-67

issue

eissn

0114-5916

issn

1179-1942

pii

2761

journal_volume

pub_type

杂志文章

在线工具

Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.